Supernus, Inc. (INDV) stock
INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SUPN
$35.37+0.12 (+0.34%)
Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –
Supernus r&d expenses
Research and development expenses are spending on new products and technology.
Supernus's R&D Expenses for the twelve months ending Sep 30, 2026 was $54.00M, down 49.5% year over year. For fiscal 2025 it was $97.00M, down 9.3% from the year before. The highest annual figure on record is $116.00M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.00M | -9.3% |
| FY2024 | Dec 31, 2024 | $107.00M | -7.8% |
| FY2023 | Dec 31, 2023 | $116.00M | +56.8% |
| FY2022 | Dec 31, 2022 | $74.00M | +42.3% |
| FY2021 | Dec 31, 2021 | $52.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.00M | -84.8% |
| Q2 FY2026 | Jun 30, 2026 | $12.00M | -42.9% |
| Q1 FY2026 | Mar 31, 2026 | $16.00M | -27.3% |
| Q4 FY2025 | Dec 31, 2025 | $21.00M | -32.3% |
| Q3 FY2025 | Sep 30, 2025 | $33.00M | +50.0% |
| Q2 FY2025 | Jun 30, 2025 | $21.00M | -19.2% |
| Q1 FY2025 | Mar 31, 2025 | $22.00M | -21.4% |
| Q4 FY2024 | Dec 31, 2024 | $31.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $22.00M | – |
| Q2 FY2024 | Jun 30, 2024 | $26.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $28.00M | – |
See a number that looks wrong?